Search Results

Press Releases

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.

July 1, 2024

·

7 min read

Press Releases

Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002

January 29, 2025

·

1 min read

Press Releases

Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO

November 4, 2024

·

2 min read

Drug Development

Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®.

October 2, 2023

·

3 min read

Pharm Country

Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

Alvotech and Kashiv Biosciences LLC announced that they have entered into an exclusive licensing agreement for AVT23, a proposed biosimilar to Xolair®, which is currently in clinical development.

October 3, 2023

·

8 min read

Business

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

Kashiv Biosciences LLC today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development.

October 3, 2023

·

9 min read

Drug Development

Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)

Kashiv Biosciences, LLC announced that ADL018, a biosimilar candidate to Xolair®, completed a successful global Phase 1 clinical study in healthy volunteers.

July 5, 2023

·

3 min read

Press Releases

Rancho BioSciences, LLC Awarded Great Place to Work(R) Certification for the Third Consecutive Year

December 12, 2024

·

2 min read

FDA

Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)

Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®.

May 31, 2022

·

4 min read

FDA

Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)

Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.

March 2, 2022

·

4 min read